Inozyme Pharma Inc Stock

$4.00

0.00%

Nasdaq, Fri, Jul 11 2025

ISIN

US45790W1080

Symbol

INZY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Inozyme Pharma Inc Stock price

$4.00

-13.54 77.20% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+0.00 0.00%

ISIN

US45790W1080

Symbol

INZY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$258.3m

Enterprise Value

$219.8m

Net debt

positive

Cash

$84.8m

Shares outstanding

64.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

8.1

Financial Health

Equity Ratio

46.9%

Return on Equity

-176.4%

ROCE

-201.4%

ROIC

Debt/Equity

1.5

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-104.7m | $-96.4m

EBIT

$-105.5m | $-103.8m

Net Income

$-106.7m | $-94.4m

Free Cash Flow

$-96.6m

EPS

$-1.7

FCF per Share

$-1.5

Short interest

5.7%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Inozyme Pharma Inc Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Inozyme Pharma Inc forecast:

6x Buy

46%

7x Hold

54%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Inozyme Pharma Inc forecast:

Buy

46%

Hold

54%

Analyst Estimates with Stock Price Targets

Financial data from Inozyme Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	21 21	7% 7% -
- Research and Development Expense	85 85	36% 36% -
EBITDA	-105 -105	30% 30% -
- Depreciation and Amortization	0.74 0.74	9% 9% -
EBIT (Operating Income) EBIT	-105 -105	29% 29% -
Net Profit	-107 -107	38% 38% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Inozyme Pharma Inc Stock News

Neutral

PRNewsWire

●

13 days ago

BioMarin Announces Completion of Acquisition of Inozyme

SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million.

Neutral

GlobeNewsWire

●

24 days ago

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).

Neutral

Business Wire

●

about 2 months ago

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozyme Pharma, Inc. (NasdaqGS: INZY) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Inozyme will receive $4.00 in cash for each share of ...

More Inozyme Pharma Inc News

Company Profile

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Head office	United States
CEO	Doug Treco
Employees	67
Founded	2015
Website	www.inozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now